Sponsors (10)
The bill speeds patient access and substitution to many biosimilars and gives clearer near‑term regulatory timelines while preserving existing exclusivity terms, but it introduces legal and regulatory uncertainty, potential safety/coverage conflicts, and risks weakening incentives for future biologic innovation.
Patients taking biologic therapies and their payers may get faster, broader access to lower‑cost biosimilar and interchangeable products because many §351(k) products are deemed interchangeable after a 60‑day transition, increasing substitution options.
Manufacturers, pharmacies, hospitals, and healthcare workers gain clearer regulatory timelines and updated criteria (guidance revisions required within 18 months), reducing regulatory uncertainty about expectations and submissions.
Holders of already‑granted first‑interchangeable exclusivity keep the remaining unexpired exclusivity term, preserving the economic value of existing exclusivity for current licensees.
Patients, payers, and providers could face confusion or conflicting determinations about whether a product is interchangeable if the statute's deemed‑interchangeability conflicts with existing FDA findings or interim guidance, risking substitution errors or coverage disputes.
Manufacturers of future biologics may see reduced exclusivity advantages and weaker incentives for follow‑on innovation if post‑enactment approvals lose expected exclusivity protections, potentially slowing development of new biologic therapies.
Narrowing statutory language to require only that the Secretary find submitted information 'sufficient to show' biosimilarity could be interpreted to lower evidentiary standards or limit FDA discretion, creating legal uncertainty about approval thresholds and litigable disputes.
Based on analysis of 2 sections of legislative text.
Amends biosimilar statute to require 'sufficient information' for biosimilarity, reorganizes subsection (k), and deems licensed (k) products interchangeable for 60 days while preserving existing exclusivities.
Amends the Public Health Service Act rules for biosimilar biologics by revising proof requirements for showing biosimilarity, reorganizing statutory subsections, and creating a 60-day transition during which products already licensed under subsection (k) are treated as interchangeable with their reference product unless blocked by an existing first‑interchangeable exclusivity. The bill also preserves any remaining exclusivity for products that earned first‑interchangeable status before enactment and directs the Secretary to issue criteria related to certain regulatory provisions.
Official title: To improve the requirements for making a determination of interchangeability of a biological product and its reference product.
Introduced September 19, 2025 by August Pfluger · Last progress September 19, 2025